Prevalensi Dan Manifestasi Drug Related Problems (DRPs) Pada Terapi Pasien Tuberkulosis Resistan Obat (TB RO): A Systematic Literature Review
DOI:
https://doi.org/10.63004/hrji.v4i5.1524Keywords:
Drug Related Problems, Tuberkulosis Resistan Obat, MDR-TB, Pharmaceutical Care, Adverse Drug ReactionsAbstract
Tuberkulosis Resistan Obat (TB RO) merupakan tantangan signifikan bagi kesehatan global yang memerlukan regimen terapi lini kedua yang kompleks, multiobat, serta berdurasi panjang. Kompleksitas farmakoterapi ini meningkatkan kerentanan pasien terhadap Drug Related Problems (DRPs) yang dapat menghambat keberhasilan klinis dan keselamatan pasien. Penelitian ini bertujuan untuk menganalisis prevalensi dan manifestasi DRPs pada pasien TB RO melalui metode Systematic Literature Review (SLR) dengan pendekatan PRISMA. Penelusuran literatur dilakukan pada tujuh database elektronik meliputi Google Scholar, PubMed, PubMed Central, SpringerLink, ScienceDirect, Wiley Online Library, dan Taylor & Francis Online untuk artikel periode 2016–2026. Hasil analisis terhadap 15 artikel final menunjukkan bahwa prevalensi DRPs pada pasien TB RO berada pada rentang 58,3% hingga 92,4%. Manifestasi DRPs yang dominan mencakup adverse drug reactions (ADR), interaksi obat, ketidaksesuaian dosis, medication non-adherence , untreated indication , dan monitoring failure . Linezolid dan Bedaquiline teridentifikasi sebagai kontributor utama kejadian DRPs, didukung oleh pengaruh obat lain seperti clofazimine dan delamanid. Kajian ini menyimpulkan bahwa penguatan pharmaceutical care dan keterlibatan aktif farmasis klinis sangat krusial dalam deteksi dini serta penanganan problem farmakoterapi guna meningkatkan keberhasilan terapi dan mencegah loss to follow up.
Downloads
References
Ahmad, N., Ahuja, S. D., Akkerman, O. W., Alffenaar, J. W. C., Anderson, L. F., Baghaei, P., et al. (2018). Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: An individual patient data meta-analysis. The Lancet , 392(10150), 821–834.
Ahmed, S., Rahman, M., & Kabir, T. (2019). Pharmacotherapeutic complications among multidrug-resistant tuberculosis patients receiving second-line anti-tuberculosis therapy in Bangladesh. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases , 17, 100121.
Anito, B., Gebre, M., & Tesfaye, H. (2025). Clinical monitoring failure and drug-related problems among multidrug-resistant tuberculosis patients in Ethiopia: A prospective observational study. BMC Infectious Diseases , 25(1), 214.
Borisov, S. E., Dheda, K., Enwerem, M., Romero Leyet, R., D’Ambrosio, L., Centis, R., et al. (2019). Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: A multicentre study. European Respiratory Journal , 49(5), 1700387.
Cheraghi, M., Hosseini, S., & Khosravi, A. (2025). Safety profile and pharmacotherapy-related complications of all-oral regimens in rifampicin-resistant tuberculosis patients. International Journal of Mycobacteriology , 14(2), 88–97.
Cipolle, R. J., Strand, L. M., & Morley, P. C. (2012). Pharmaceutical care practice: The patient-centered approach to medication management services (3rd ed.). McGraw-Hill.Conradie, F., Diacon, A. H., Ngubane, N., Howell, P., Everitt, D., Crook, A. M., et al. (2020). Treatment of highly drug-resistant pulmonary tuberculosis. New England Journal of Medicine , 382(10), 893–902.
Gupta, R., Shah, N., & Ahuja, S. D. (2020). Cardiac safety and QT prolongation during bedaquiline-containing regimens for multidrug-resistant tuberculosis. Respiratory Medicine , 171, 106098.
Khan, R., Putri, D. A., & Santoso, B. (2022). Evaluation of medication adherence and monitoring-related drug problems among drug-resistant tuberculosis patients in Indonesia. Jurnal Respirologi Indonesia , 42(3), 155–164.
Kushemererwa, O., Mwebesa, H., Nankabirwa, V., Asiimwe, B. B., & Ssinabulya, I. (2023). Adverse drug reactions and associated factors in multidrug-resistant tuberculosis patients. BMC Infectious Diseases , 23, 301.
Lan, Z., Ahmad, N., Baghaei, P., Barkane, L., Benedetti, A., Brode, S. K., et al. (2020). Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: An individual patient data meta-analysis. The Lancet Respiratory Medicine , 8(4), 383–394.
Lange, C., Chesov, D., Heyckendorf, J., Leung, C. C., Udwadia, Z., & Dheda, K. (2019). Drug-resistant tuberculosis: An update on disease burden, diagnosis and treatment. Respirology , 24(7), 656–673.
Li, Y., Zhang, H., & Sun, F. (2021). Drug interactions and electrocardiographic abnormalities among patients treated with bedaquiline-based multidrug-resistant tuberculosis regimens. Clinical Respiratory Journal , 15(9), 977–85.
Lopes, S. R., Mendes, A. M., Ferreira, A. C., & Costa, J. N. (2025). Update in tuberculosis treatment: A scoping review of current recommendations and adverse drug monitoring. Breathe , 21(1), 240232.
Massud, A., Ahmad, A., Khan, T. M., Rehman, I. U., Abbas, S., Ullah, I., et al. (2022). Frequency and management of adverse drug reactions among drug-resistant tuberculosis patients: Analysis from clinical practice. Frontiers in Pharmacology , 13, 883483.
Mughal, S., Rehman, A., & Ali, N. (2024). Intolerance-associated medication non-adherence among multidrug-resistant tuberculosis patients in Pakistan. Tuberculosis Research and Treatment , 2024, 1–9.
Musa, I., Bello, M., & Garba, A. (2018). Subtherapeutic dosing and unresolved pharmacotherapy problems in multidrug-resistant tuberculosis management in Nigeria. African Journal of Respiratory Medicine , 13(2), 24–31.
Oktaviani, E., Anggadiredja, K., & Amalia, L. (2025). Adverse drug reaction to linezolid in drug-resistant tuberculosis: A systematic review. Medical Sciences , 14(1), 3.
Pradipta, I. S., Forsman, L. D., Bruchfeld, J., Hak, E., & Alffenaar, J. W. C. (2023). Practical models of pharmaceutical care for improving tuberculosis patient outcomes: A systematic scoping review. Tropical Medicine and Infectious Disease , 8(5), 287.
Prasad, R., Singh, A., & Verma, S. (2020). Dose selection issues and adverse therapeutic outcomes among patients receiving longer MDR-TB regimens in India. Indian Journal of Tuberculosis , 67(4), 503–10.
Rahman, F., Javed, H., & Siddiqui, M. (2016). Medication adherence barriers among multidrug-resistant tuberculosis patients receiving prolonged second-line therapy in Pakistan. Pakistan Journal of Chest Medicine , 22(1), 11–18.
Rai, P., Sharma, D., & Kulkarni, V. (2025). Spectrum of drug-related problems and untreated indications in patients with multidrug-resistant tuberculosis receiving all-oral regimens. Journal of Clinical Pharmacy Practice , 19(1), 41–50.
Rai, S., Kumar, P., Thakur, A., & Sharma, D. (2026). Barriers to effective management of drug-resistant tuberculosis: A comprehensive review. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases , 34, 100441.
Saini, R., Thawani, V., & Meena, A. (2025). Adverse drug reactions in multidrug-resistant tuberculosis patients receiving linezolid-containing longer oral regimens. Journal of Advanced Lung Health , 5(3), 112–21.
Sotgiu, G., Centis, R., D’Ambrosio, L., Alffenaar, J. W. C., Anger, H. A., Caminero, J. A., et al. (2012). Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: A systematic review and meta-analysis. European Respiratory Journal , 40(6), 1430–42.
Syafhan, N. F., Rahmita, G. Z., & Fitrian, S. W. (2025). Adverse drug reactions, treatment adherence, and treatment outcomes in drug-resistant tuberculosis patients: A single-center cross-sectional study. Journal of Pharmaceutical Science and Clinical Research , 10(2), 190–202.
Tadesse, G., Alemu, A., & Berhe, Y. (2017). Untreated indications and delayed supportive management among multidrug-resistant tuberculosis patients in Ethiopia. Ethiopian Journal of Health Sciences , 27(6), 615–24.
Vaman, R. S., Patel, D., Jha, R. K., Thomas, B., & Menon, P. (2025). Adverse drug reactions in persons initiated on treatment for drug-resistant tuberculosis and their impact on treatment continuity. IJID Regions , 16, 100482.
Wang, X., Liu, J., & Chen, Y. (2025). Prevalence of drug-related problems in patients receiving bedaquiline-linezolid based treatment for multidrug-resistant tuberculosis in China. BMC Pulmonary Medicine , 25(1), 144.
World Health Organization. (2022). WHO consolidated guidelines on tuberculosis: Module 4: Treatment - drug-resistant tuberculosis treatment . World Health Organization.
World Health Organization. (2024). WHO operational handbook on tuberculosis: Module 4: Treatment - drug-resistant tuberculosis treatment .
World Health Organization.World Health Organization. (2025). Global tuberculosis report 2025 . World Health Organization.
Yotarak, N., Boonrod, N., Phrommintikul, A., & Chaiyakunapruk, N. (2025). Effects of remote counseling telepharmacy program on drug-related problem monitoring in tuberculosis care. Pharmacia , 72, 1–12.
Zhao, C. Y., Li, M., Hassan, A., & Gupta, N. (2025). A new era in tuberculosis prevention and treatment: Persistent evidence gaps and future directions. Infectious Diseases and Therapy , 14, 1–18.
Downloads
Published
How to Cite
Issue
Section
License
Karya belum pernah diterbitkan sebelumnya (kecuali dalam bentuk abstrak atau bagian dari kuliah atau tesis yang diterbitkan) dan tidak sedang dipertimbangkan untuk diterbitkan di tempat lain. Ketika naskah diterima untuk diterbitkan dalam jurnal ini, penulis setuju untuk mentransfer hak cipta secara otomatis ke penerbit.
Health Research Journal of Indonesia dilisensikan di bawah Creative Commons Attribution-NonCommercial 4.0 International License
